Humanin Peptide

The discovery paper that introduced Humanin to the scientific community came from Hashimoto and colleagues (2001), who identified the peptide while screening a cDNA library constructed from the surviving occipital cortex of a patient with Alzheimer disease (AD). The 24-residue peptide was named "Humanin" to reflect its potential cytoprotective role in maintaining human neuronal viability. This study established Humanin as the first known mitochondria-derived peptide (MDP) encoded within the 16S rRNA region of mitochondrial DNA (MT-RNR2).

Study Design

• Model: F11 neurohybrid cells exposed to multiple AD-related cytotoxic insults including familial AD (FAD) mutant amyloid precursor protein (APP), mutant presenilin-1 (PS1), mutant presenilin-2 (PS2), and amyloid-beta (Aβ) peptides (Aβ1-43, Aβ1-42, Aβ25-35)
• Intervention: Synthetic Humanin (HN) peptide added to culture medium at concentrations ranging from 1 nM to 10 μM
• Endpoints: Cell viability via WST-8 assay, apoptosis quantification, structure-activity relationship via alanine scanning

Key Results

• Humanin completely suppressed neuronal death induced by all tested FAD-related insults at concentrations ≥1 μM
• Effective concentration (EC50) for Aβ1-43 toxicity rescue was approximately 10 nM
• Substitution of Ser-7, Leu-9, Leu-12, Thr-13, or Ser-14 with alanine abolished activity, defining the core functional domain
• The S14G substitution (HNG) produced a 1,000-fold more potent variant, widely used in subsequent research
• Humanin did not rescue death from non-AD insults such as superoxide dismutase mutations or staurosporine, demonstrating mechanistic specificity

The selectivity of Humanin for AD-related apoptotic pathways suggested it acts upstream of common apoptotic effectors rather than as a broad anti-apoptotic agent. Subsequent biochemical work confirmed direct binding to Bax, IGFBP-3, and a heterotrimeric receptor complex composed of CNTFR/WSX-1/gp130 — findings that distinguished Humanin from conventional growth factors and small-molecule neuroprotectants.

This landmark paper has been cited in over 800 subsequent investigations and established the entire field of mitochondria-derived peptide research, paving the way for the later discovery of MOTS-c and the SHLP family.

A pivotal mechanistic study by Guo et al. (2003) published in Nature demonstrated that Humanin exerts its cytoprotective effect in part by directly binding to and inhibiting Bax, a pro-apoptotic Bcl-2 family protein responsible for mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release. This was the first identification of an endogenous peptide that antagonizes Bax translocation.

Study Design

• Models: HeLa cells, mouse embryonic fibroblasts (Bax+/+ and Bax-/-), and isolated mitochondria
• Intervention: Recombinant Humanin co-administered with staurosporine, etoposide, or Bax-activating BH3 peptides
• Endpoints: Co-immunoprecipitation, mitochondrial Bax translocation, cytochrome c release, caspase-3 activation

Key Results

• Humanin directly bound Bax with a dissociation constant (Kd) of approximately 140 nM
• Binding prevented activation-induced conformational change in Bax and blocked its translocation from cytosol to mitochondria
• Cytochrome c release was reduced by >80% in Humanin-treated cells
• Bax-deficient cells showed no additional protection from Humanin, confirming Bax as the primary target in this pathway
• Humanin did not interact with Bak, Bcl-2, or Bcl-xL, indicating selectivity

This finding placed Humanin among the small group of known endogenous Bax inhibitors and provided a structural basis for its anti-apoptotic activity that complements its receptor-mediated signaling through CNTFR/WSX-1/gp130. The dual mechanism — extracellular receptor engagement triggering STAT3 survival signaling plus intracellular Bax sequestration — explains why Humanin protects against such a wide range of apoptotic stimuli including ischemia, oxidative stress, and amyloid toxicity.

Subsequent work by Zhai et al. (2005) extended these observations to cardiomyocyte ischemia-reperfusion injury models, where Humanin pretreatment reduced infarct size by approximately 50% in murine myocardial ischemia experiments, again via Bax-dependent mechanisms. These cardioprotective findings have positioned Humanin as a research tool of interest in studies of mitochondrial dysfunction beyond the central nervous system.

Beyond its neuroprotective profile, Humanin has been extensively characterized as a metabolic regulator. A landmark investigation by Muzumdar and colleagues (2009) examined the effects of the potent Humanin analog HNG (S14G-Humanin) on glucose homeostasis and insulin action in rodent models. The study used Sprague-Dawley rats subjected to hyperinsulinemic-euglycemic clamps following acute intracerebroventricular (ICV) and peripheral administration of HNG.

Study Design

• Subjects: Male Sprague-Dawley rats and Zucker diabetic fatty (ZDF) rats
• Intervention: ICV infusion of HNG at 10 ng/h, or peripheral HNG administration (0.25 mg/kg)
• Duration: Acute (3-hour clamp studies) and sub-chronic (multi-day dosing in ZDF rats)
• Primary endpoints: Hepatic glucose production (HGP), peripheral glucose uptake, fasting glucose, and insulin levels

Key Results

• Central HNG infusion suppressed hepatic glucose production by approximately 43% during the clamp, indicating enhanced hepatic insulin sensitivity
• Peripheral HNG administration reproduced the suppression of HGP, demonstrating systemic bioactivity
• In ZDF rats, sub-chronic HNG treatment significantly reduced fasting hyperglycemia and improved glucose tolerance
• Effects were mediated through activation of hypothalamic STAT3 signaling, consistent with a CNS-mediated insulin-sensitizing axis

Context and Significance

This work positioned Humanin as the first mitochondria-derived peptide (MDP) with demonstrated insulin-sensitizing properties via central nervous system signaling. Plasma Humanin levels are known to decline with age in both humans and rodents, paralleling the development of insulin resistance. The findings established a mechanistic link between mitochondrial-encoded peptides and whole-body metabolic homeostasis, predating similar findings for MOTS-c by several years. Subsequent investigations have shown that circulating Humanin levels are inversely correlated with markers of metabolic syndrome, suggesting that the decline of MDPs may contribute to age-associated metabolic dysfunction.¹

The study also demonstrated that HNG, with its single S14G substitution, exhibits approximately 1,000-fold greater potency than wild-type Humanin in many bioassays, making it a preferred research tool for in vivo studies where wild-type Humanin's short half-life and modest potency are limiting factors.

The cytoprotective properties of Humanin extend beyond the central nervous system to ischemic injury in peripheral tissues. Muzumdar and colleagues (2010) investigated the cardioprotective effects of the Humanin analog HNG in a murine model of myocardial ischemia-reperfusion (I/R) injury, providing some of the first evidence that mitochondria-derived peptides can attenuate acute cardiac ischemic damage.

Study Design

• Model: C57BL/6 mice subjected to 30 minutes of left anterior descending (LAD) coronary artery occlusion followed by 24 hours of reperfusion
• Intervention: Intraperitoneal HNG (2 mg/kg) administered prior to ischemia or at the onset of reperfusion
• Primary endpoints: Infarct size (relative to area at risk), serum troponin I, apoptosis markers, and mitochondrial function in cardiomyocytes

Key Results

• HNG administration reduced myocardial infarct size by approximately 56% compared with vehicle-treated controls
• Serum troponin I, a marker of cardiomyocyte injury, was significantly decreased in HNG-treated animals
• HNG suppressed caspase-3 activation and TUNEL-positive nuclei in the area at risk, indicating reduced apoptotic cell death
• Cardioprotection was preserved even when HNG was administered at reperfusion, suggesting clinical relevance for post-event interventions in research models
• Mechanistic studies implicated activation of STAT3 signaling and inhibition of Bax-mediated mitochondrial permeability transition

Context and Significance

This investigation demonstrated that the anti-apoptotic mechanisms previously characterized in neurons—particularly the inhibition of pro-apoptotic Bax translocation to mitochondria—translate to cardiomyocyte protection in vivo. The magnitude of infarct size reduction (~56%) is comparable to or exceeds that observed with established cardioprotective strategies such as ischemic preconditioning in preclinical models.¹

The findings have informed broader research into mitochondria-derived peptides as endogenous protective factors. Reduced circulating Humanin levels have been observed in patients with cardiovascular disease and in aged populations, suggesting that the age-associated decline of Humanin may contribute to increased vulnerability to ischemic injury. This study established a framework for investigating Humanin and its analogs as research tools in models of acute organ ischemia, including stroke, renal I/R, and hepatic I/R injury.